PR Newswire
22 Aug 2022, 17:30 GMT+10
Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company's development of ocular tissue rejuvenation therapeutics
MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic products as an advisor to the company.
A board-certified ophthalmologist and fellowship-trained specialist in oculoplastic and orbital surgery, Wu's academic work has focused on developing treatments for vision loss and eye disease.
At Turn Bio, he will shepherd work on TRN-004, a formulation to rejuvenate ocular tissues, including corneal, limbal and conjunctival epithelial cells, as well as corneal endothelial cells. Preclinical results show the formulation reduces inflammation, oxidative stress, and cell senescence.
TRN-004 is a tailored protein cocktail to rejuvenate targeted cells in the eye. It is produced using Turn Bio's unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform.
"Albert's life mission is to transform ophthalmology by making regenerative medicine an accepted treatment for people worldwide suffering from diseases of the eye," said Anja Krammer, the company's CEO. "His vision and experience will help us redefine how eye doctors treat age-related vision conditions for which no real cure exists."
Wu has nearly two decades of experience with ophthalmology and cellular biology. He has been honored by the National Institutes of Health, American Society of Ophthalmic Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, the University of Washington and Yale University.
"Our work has the potential to revolutionize eye care to preserve patients' vision and, ultimately, restore it," said Wu. "The ability to produce cell rejuvenation therapies and deliver them with pinpoint accuracy offers enormous promise to millions of people around the world whose sight has been compromised by untreatable conditions."
Wu received his bachelor's degree in Molecular Biophysics and Biochemistry from Yale University, his medical degree and doctoral degree in Molecular and Cellular Biology from the University of Washington. He has co-authored 55 articles on his research discoveries and has contributed to textbooks on ophthalmology and ophthalmologic oncology. He is a frequent presenter at national and international medical conferences.
ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level. The company's proprietary mRNA platform technology, ERA, restores optimal gene expression by combatting the effects of aging in the epigenome. This restores the cells' ability to prevent or treat disease, heal or regenerate tissue and fight incurable chronic diseases.
The company is currently completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteo-arthritis and the muscular system. For more information, see www.turn.bio.
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup
[email protected] or (312) 543-9026
SOURCE Turn Biotechnologies, Inc.
Get a daily dose of Asia Pacific Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Pacific Star.
More InformationMANILA, Philippines - In a dramatic move, the International Criminal Court on Tuesday arrested the former president of the Philippines,...
BENTONVILLE, Arkansas: Walmart is pressuring some Chinese suppliers to cut prices in response to President Donald Trump's imposed U.S....
NEW DELHI, India: The United States is pressing India to lower tariffs and increase defense purchases to secure a stronger bilateral...
BEIJING, China: China has set an economic growth target of around five percent for 2025, signaling efforts to stabilize the economy...
Bengaluru (Karnataka) [India], March 13 (ANI): What's common between Virat Kohli and Moya Dodd? Both have challenged the norm and championed...
New Delhi [India], March 13 (ANI): Maharahtra Chief Minister Devendra Fadnavis announced on Thursday that Mumbai will host the 'WAVES...
NEW YORK, New York - The knee-jerk introduction of trade tariffs by President Donald Trump continues to rattle markets with all the...
FRANKFURT, Germany: Ford announced this week that it will inject up to $4.8 billion into its struggling German unit to stabilize its...
SEATTLE, Washington: Boeing has revamped its employee incentive plan, tying annual bonuses for more than 100,000 workers to overall...
WINNIPEG, Manitoba: Farmers in the U.S. and Canada are bracing for soaring fertilizer prices as trade tensions escalate between the...
NEW YORK, New York - A slightly lower-than-expected CPI reading for February helped U.S. stocks to stabilize after some relentless...
NEW YORK CITY, New York: New York's office market is showing signs of a comeback as major investors, including Blackstone, scout for...